Insertable Cardiac Monitors Patents: Who Leads, Where Gaps Are 2026
Insertable Cardiac Monitor Patents: Ownership, Filing Trends and Open Claim Space
90.0% concentration. The top 5 of 26 ranked assignees hold 911 of 1,012 records in scope — a field with almost no room left at the centre of the claim map. Filings peaked at 131 in 2017. The last year that can be read as a complete data point is 2024, at 56 — down from 120 in 2021, a 53% drop across that three-year span. 2025 and 2026 figures will continue to rise as publications catch up with roughly an 18-month filing-to-publication lag; they should not yet be read as a further decline.
- 1MEDTRONIC INC515
- 2PACESETTER INC131
- 3ATACOR MEDICAL INC122
- 4CARDIAC PACEMAKERS INC85
- 5CAMERON HEALTH INC58
See the full insertable cardiac monitors analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on insertable cardiac monitor patents
Who holds the most patents on insertable cardiac monitors?
Ownership in this field is highly concentrated: the leading assignee alone accounts for 515 of the 1,012 records in scope, and the top five assignees together hold 90.0% of all records. The remaining filers form a long tail, with counts dropping to single digits by tenth place. This means freedom-to-operate analysis in the implant-hardware core realistically only needs to focus on a handful of companies, not the full 26-name ranking.
Is the insertable cardiac monitor patent field still growing?
Filing activity peaked in 2017 at 131 records and has since declined, falling from 120 in 2021 to 56 in 2024, a 53% drop across that span. 2024 is the last year that can be treated as a complete data point; 2025 and 2026 figures will keep rising as publications catch up, since publication typically lags filing by about 18 months. The honest read is a maturing, heavily-claimed core rather than a shrinking field.
Where is there still open claim space in insertable cardiac monitors?
The core diagnosis-and-surgery (A61B) and electrotherapy (A61N) classes are saturated, covering 68.2% and 60.8% of all 1,012 records respectively. Transmission (H04B), power supply management (H02J) and AI-based signal computing (G06N) each sit at or below 1.9% of records, marking them as comparatively thin. Anyone targeting remote data transmission, battery longevity management or AI-based false-episode discrimination is filing into much lower-density claim territory than the implant-housing core.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Insertable Cardiac Monitors covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.